 Akers Biosciences, Inc. the Company AKER, a developer of rapid health information technologies, today announced that its collaboration with Premas Biotech has successfully completed the milestone of obtaining clones of all three coronavirus antigens, Spike S, Envelope E, and Membrane M that they have selected for their vaccine candidate. Premas Biotech develops novel technologies and partners with global biopharmaceutical companies to build and develop novel biotherapeutic vaccine candidates. 